| __timestamp | Amphastar Pharmaceuticals, Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 3932000000 |
| Thursday, January 1, 2015 | 174172000 | 3909000000 |
| Friday, January 1, 2016 | 150976000 | 4946000000 |
| Sunday, January 1, 2017 | 149380000 | 6066000000 |
| Monday, January 1, 2018 | 187681000 | 6547000000 |
| Tuesday, January 1, 2019 | 190434000 | 8078000000 |
| Wednesday, January 1, 2020 | 206506000 | 11773000000 |
| Friday, January 1, 2021 | 238029000 | 9940000000 |
| Saturday, January 1, 2022 | 250127000 | 10137000000 |
| Sunday, January 1, 2023 | 293274000 | 10693000000 |
| Monday, January 1, 2024 | 11949000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Bristol-Myers Squibb Company and Amphastar Pharmaceuticals, Inc. have shown distinct cost of revenue trends. Bristol-Myers Squibb, a titan in the industry, saw its cost of revenue grow by approximately 172%, peaking in 2020. This surge reflects its aggressive expansion and investment in research and development. In contrast, Amphastar Pharmaceuticals, a smaller player, experienced a more modest increase of around 84% over the same period. This steady growth highlights its strategic focus on niche markets and cost efficiency. The data reveals a fascinating narrative of how two companies navigate financial challenges and opportunities in a competitive landscape. As the pharmaceutical sector continues to innovate, these trends offer valuable insights into the financial strategies of industry leaders.
AbbVie Inc. vs Bristol-Myers Squibb Company: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: AstraZeneca PLC vs Amphastar Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Bristol-Myers Squibb Company
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Incyte Corporation
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Pharming Group N.V.
Cost Insights: Breaking Down Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: GSK plc and Amphastar Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Cytokinetics, Incorporated and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.